biperiden Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	374	514-65-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: biperiden akineton biperiden hydrochloride biperiden lactate biperiden HCl	A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine. Molecular weight: 311.47 Formula: C21H29NO CLOGP: 4.94 LIPINSKI: 0 HAC: 2 HDO: 1 TPSA: 23.47 ALOGS: -4.86 ROTB: 5 Status: OFM Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

biperiden
akineton
biperiden hydrochloride
biperiden lactate
biperiden HCl

A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine.

Molecular weight: 311.47
Formula: C21H29NO
CLOGP: 4.94
LIPINSKI: 0
HAC: 2
HDO: 1
TPSA: 23.47
ALOGS: -4.86
ROTB: 5

Status: OFM

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
10	mg	O
10	mg	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	1 mg/mL	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.64 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	30 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
fu (Fraction unbound in plasma)	0.10 %	Lombardo F, Berellini G, Obach RS
Vd (Volume of distribution)	12 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	12 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	24 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Sept. 8, 1959	FDA	ABBVIE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Suicide attempt	197.71	56.19	48	414	11234	2346389
Neuroleptic malignant syndrome	178.65	56.19	33	429	2047	2355576
Intentional overdose	166.99	56.19	42	420	11279	2346344
Sopor	145.64	56.19	31	431	3964	2353659
Intentional self-injury	127.70	56.19	28	434	4099	2353524
Somnolence	111.41	56.19	36	426	23449	2334174
Delirium	100.04	56.19	24	438	5199	2352424
Dyskinesia	96.86	56.19	23	439	4766	2352857
Confusional state	90.12	56.19	31	431	24313	2333310
Drug abuse	89.00	56.19	26	436	12000	2345623
Tremor	87.02	56.19	29	433	20632	2336991
Inappropriate affect	85.15	56.19	13	449	244	2357379
Coma	82.31	56.19	23	439	9033	2348590
Logorrhoea	76.79	56.19	13	449	476	2357147
Extrapyramidal disorder	67.30	56.19	15	447	2332	2355291
Urinary incontinence	63.45	56.19	16	446	4217	2353406
Disorganised speech	61.33	56.19	9	453	127	2357496
Agitation	56.43	56.19	18	444	11033	2346590

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Neuroleptic malignant syndrome	247.84	57.00	51	454	3097	1743179
Intentional self-injury	208.30	57.00	43	462	2630	1743646
Delirium	151.31	57.00	39	466	6323	1739953
Disorientation	103.32	57.00	28	477	5441	1740835
Intentional overdose	93.95	57.00	28	477	7642	1738634
Sopor	86.93	57.00	20	485	1981	1744295
Confusional state	86.74	57.00	34	471	21244	1725032
Ileus paralytic	77.51	57.00	16	489	951	1745325
Suicide attempt	73.47	57.00	23	482	7358	1738918
Sedation	71.49	57.00	19	486	3398	1742878
Altered state of consciousness	71.06	57.00	19	486	3478	1742798
Coma	69.64	57.00	22	483	7240	1739036
Overdose	69.01	57.00	27	478	16674	1729602
Hyponatraemia	68.98	57.00	23	482	8977	1737299
Agitation	68.23	57.00	24	481	11002	1735274
Restlessness	67.07	57.00	19	486	4302	1741974
Intentional product misuse	65.22	57.00	21	484	7337	1738939
Dyskinesia	60.19	57.00	17	488	3802	1742474
Condition aggravated	59.54	57.00	26	479	21124	1725152
Blood creatine phosphokinase increased	57.50	57.00	20	485	8836	1737440

Pharmacologic Action:

Source	Code	Description
ATC	N04AA02	NERVOUS SYSTEM ANTI-PARKINSON DRUGS ANTICHOLINERGIC AGENTS Tertiary amines
CHEBI has role	CHEBI:136860	antidote to sarin poisoning
CHEBI has role	CHEBI:66956	antidyskinesia agent
CHEBI has role	CHEBI:48876	muscarinic antagonist
CHEBI has role	CHEBI:50370	parasympatholytic
CHEBI has role	CHEBI:48407	antiparkinson drug
MeSH PA	D018726	Anti-Dyskinesia Agents
MeSH PA	D000978	Antiparkinson Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D018678	Cholinergic Agents
MeSH PA	D018680	Cholinergic Antagonists
MeSH PA	D018727	Muscarinic Antagonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D010276	Parasympatholytics
MeSH PA	D018373	Peripheral Nervous System Agents
FDA EPC	N0000175574	Anticholinergic

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Postencephalitic parkinsonism	indication	19972008	DOID:14332
Parkinsonism	indication	32798002
Parkinson's disease	indication	49049000	DOID:14330
Extrapyramidal disease	indication	76349003
Arteriosclerotic Parkinsonism	indication
Urinary tract obstruction	contraindication	7163005	DOID:5200
Chronic obstructive lung disease	contraindication	13645005	DOID:3083
Severe chronic ulcerative colitis	contraindication	14311001
Disorder of autonomic nervous system	contraindication	15241006
Toxic megacolon	contraindication	28536002	DOID:1770
Atony of colon	contraindication	29479008
Shigellosis	contraindication	36188001
Hypertensive disorder	contraindication	38341003	DOID:10763
Conduction disorder of the heart	contraindication	44808001
Low blood pressure	contraindication	45007003
Achalasia of esophagus	contraindication	45564002	DOID:9164
Chronic heart failure	contraindication	48447003
Dysuria	contraindication	49650001
Paralytic ileus	contraindication	55525008	DOID:8442
Ulcerative colitis	contraindication	64766004	DOID:8577
Hiatal hernia	contraindication	84089009	DOID:12642
Open-angle glaucoma	contraindication	84494001	DOID:1067
Kidney disease	contraindication	90708001	DOID:557
Thyrotoxicosis	contraindication	90739004	DOID:7997
Myasthenia gravis	contraindication	91637004	DOID:437
Tardive dyskinesia	contraindication	102449007
Dysentery	contraindication	111939009
Gastrointestinal obstruction	contraindication	126765001
Bleeding	contraindication	131148009
Gastroesophageal reflux disease	contraindication	235595009	DOID:8534
Disease of liver	contraindication	235856003	DOID:409
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Fever	contraindication	386661006
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Pseudomembranous enterocolitis	contraindication	397683000
Gastric ulcer	contraindication	397825006	DOID:10808
Disorder of coronary artery	contraindication	414024009

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.2	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN	ANTAGONIST	Kd	9.32	IUPHAR	CHEMBL
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	8.20	PDSP
Neuronal acetylcholine receptor subunit alpha-2	Ion channel	Q15822	ACHA2_HUMAN				WOMBAT-PK
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN	ANTAGONIST	Kd	8.20	IUPHAR
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN	ANTAGONIST	Kd	8.41	IUPHAR
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN	ANTAGONIST	Kd	8.62	IUPHAR

External reference:

ID	Source
D001712	MESH_DESCRIPTOR_UI
4019635	VUID
N0000147728	NUI
C0005578	UMLSCUI
D00779	KEGG_DRUG
09TD6C5147	UNII
7085-45-2	SECONDARY_CAS_RN
915	INN_ID
65041000	SNOMEDCT_US
4019635	VANDF
001644	NDDF
1589	RXNORM
387359004	SNOMEDCT_US
4285	MMSL
d00972	MMSL
CHEMBL1101	ChEMBL_ID
DB00810	DRUGBANK_ID
CHEBI:3112	CHEBI
7128	IUPHAR_LIGAND_ID
2381	PUBCHEM_CID
CHEMBL1201035	ChEMBL_ID
CHEMBL1201067	ChEMBL_ID
C036432	MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

None